Cannabix Technologies Inc. (BLOZF)
OTC PINK OTC PINK Primary 
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) reports that early testing by Omega Laboratories Inc (“Omega Laboratories” or “Omega”) with the Company's marijuana breathalyzer technology have garnered positive results. Omega has commenced pre-validation scoping work to establish limits of detection (LOD) and limits of quantification (LOQ) as well as the cutoff level for the detection of delta-9 THC (primary psychoactive ingredient in cannabis) in breath. Recently, Cannabix entered into a strategic partnership and development agreement with Omega Laboratories to advance the development and commercialization of the Cannabix marijuana breathalyzer technology. Omega Laboratories is an international industry leader in forensic drugs of abuse testing with multiple international certifications and accreditations.
Cannabix Technologies Annual General and Special Meeting Results
VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company”) announces the results of its annual general and special meeting of common shareholders held on June 18, 2024 in Vancouver. Resolutions passed at the meeting included the appointment of Saturna Group Chartered Accountants LLP as auditors for the ensuing year, an ordinary resolution to approve the adoption of the Company's Stock Option Incentive Plan and the granting of stock options thereunder in an amount up to 15% of the total issued and outstanding shares, an ordinary resolution to approve the adoption of the Company's Restricted Share Unit Incentive Plan and the granting of equity awards thereunder in an amount up to 5% of the total issued and outstanding shares, and the election of Dr. Raj Attariwala, Dr. Phillip Olla, Rav Mlait, Bryan Loree, and Thomas Clarke as directors.
